Zenas BioPharma

We are a global biopharmaceutical company driven by a deep commitment to becoming a leader in the development and commercialization of immunology-based therapies for patients around the world. Our mission is to enable patients with autoimmune diseases to reimagine their lives. We are a proven team, dedicated to developing therapies for autoimmune diseases where there are significant opportunities to address unmet patient needs and truly transform lives. We act with purpose and urgency, fueled by curiosity and compassion, as we strive to understand the experiences of patients. This understanding is what drives us to introduce transformative new therapies that help them realize the lives they always intended to live.

Our core strategy is built on the foundation of our experienced leadership team and a disciplined approach to acquiring and developing promising product candidates. We are focused on identifying therapies that we believe can offer superior clinical benefits to those living with autoimmune diseases. Our lead product candidate, obexelimab, is a testament to this strategy. It is an investigational, bifunctional monoclonal antibody designed to bind to both CD19 and FcγRIIb, which are broadly present across the B cell lineage. This unique mechanism allows it to suppress the activity of B cells, a key contributor to many autoimmune diseases, without depleting them. We are rapidly advancing our programs, including obexelimab, through clinical trials with the potential to address significant unmet medical needs. We believe in doing more, together, because patients with autoimmune diseases deserve more: more transformative therapies, more treatment options, and more opportunities to feel good and live life to the fullest.